Risankizumab

What is Risankizumab

Risankizumab, an interleukin-23 antagonist, is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Treatment with risankizumab may increase the risk of infections. Caution is advised when administering the drug to patients with a history of chronic or recurrent infections.

Prior to initiating therapy, all potential drug recipients must be evaluated for tuberculosis (TB) infections.

Do not administer risankizumab to patients with active TB infection; patients with latent TB should initiate treatment before receiving.

Brand Name

Skyrizi

Indications

  • psoriasis

For the treatment of moderate to severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy

Side Effects

  1. antibody formation
  2. asthenia
  3. bleeding
  4. edema
  5. erythema
  6. fatigue
  7. folliculitis
  8. headache
  9. hematoma
  10. infection
  11. injection site reaction
  12. osteomyelitis
  13. pharyngitis
  14. pruritus
  15. rhinitis
  16. sinusitis
  17. urticaria

Monitoring Parameters

  • tuberculin skin test

Contraindications

  • breast-feeding
  • immunosuppression
  • infection
  • pregnancy
  • tuberculosis
  • vaccination

Interactions

  • Bacillus Calmette-Guerin Vaccine, BCG
  • Influenza Virus Vaccine
  • Intranasal Influenza Vaccine
  • Live Vaccines
  • Measles Virus; Mumps Virus; Rubella Virus; Varicella Virus Vaccine, Live
  • Measles/Mumps/Rubella Vaccines, MMR
  • Rotavirus Vaccine
  • Rubella Virus Vaccine Live
  • Smallpox and Monkeypox Vaccine, Live, Nonreplicating
  • Smallpox Vaccine, Vaccinia Vaccine
  • Typhoid Vaccine
  • Varicella-Zoster Virus Vaccine, Live
  • Yellow Fever Vaccine, Live
15585

Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

15856
Scroll to Top